Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2012 (Vol. 32, No. 4)

Getting the Most from Outsourced Projects

  • Making outsourcing an efficient and effective option for biotechnology manufacturing often is dependent upon innovation, a keen awareness of potential risks, and close collaborative relationships between CMOs and their clients. Recipharm Pharmaceutical Development and PledPharma are reaping the benefits of their close collaboration now. In early January, Recipharm gained regulatory approval from the Swedish Medical Products Agency to begin manufacturing PledPharma’s mangafodipir, thus allowing Phase IIa trials in myocardial infarction to begin in January.

    “After being contacted by PledPharma, both companies worked very hard to get the clinical trial material approved as fast as possible and were very happy with the result,” according to Maria Lundberg, GM at Recipharm. “PledPharma managed the regulatory contacts, and Recipharm compiled module 3 of the IMPD and justified the differences from the old manufacturing process.”

    That experience speaks to the close collaborations that are expected between contract manufacturing organizations and their clients. In working with PledPharma, Lundberg says that close collaboration and frequent communication was essential. “Geographic proximity, as both companies are located in the Stockholm area, has allowed frequent fact-to-face meetings, which has greatly facilitated the collaboration.”

    “The most important element to any collaboration like this is not the type of relationship—preferred supplier or functional service provider—but simply the strong sense of trust between the parties,” Lundberg says.

    “It is impossible to foresee all problems at the outset that might occur and describe remedies in a contract. Therefore, you have to trust that your partner will solve any unexpected challenges.” Lundberg cites reliability; professional, strong technical and scientific competence; entrepreneurship; and tenacity as key. “Applying these principles in any development project will enable partners to build strong relationships and efficiently overcome any problems as they occur.”

  • Innovation

    Click Image To Enlarge +
    DSM says it is always looking to increase its value proposition for clients. One of its innovations is its XD technology, which, it claims, allows scientists to maximize output from disposable bioreactors.

    DSM, as a full-service, global contract manufacturing organization, uses its capacity for innovation to increase its value proposition for clients. Its pharmaceutical products division focuses upon innovative biologics, pharmaceutical chemicals, pharmaceuticals, and biosolutions.

    “DSM Pharma Biotech’s innovations result in a much lower cost of goods and better sustainability by significantly reducing water and energy usage per gram or kilogram of material produced,” according to Karen King, president, DSM Biologics.

    During the past year, DSM Biologics has scaled up its XD® technology and began actively promoting its downstream technologies, Rhobust® and Kremer Method™. These three products are fully compatible with single-use as well as commercial-scale technologies and allow more advanced process control, which is particularly important for new molecules and biosimilars.

    XD technology is designed for mammalian cell lines. “It allows clients to maximize output from disposable bioreactors. Typically, XD has increased product titers by a factor of 8–10 times,” King says. “Therefore, a 250 L bioreactor can provide the same amount of drug substances as a 2,500 L stainless steel bioreactor, at an overall lower cost.” It also speeds development time by reducing the need to optimize cell-line productivity.

    The Rhobust technology is next-generation expanded bed chromatography, using cross-linked agarose beads with tungsten carbine to increase particle density. This direct-capture step increases the yield of mammalian and microbial harvests, and reduces the number of unit operations and costs of goods, King explains.

    The Kremer Method is used after the capture step, streamlining the protein purification and polishing steps into one single unit operation. “Using this method, host cell proteins were removed to a level below the limits of detection, complete aggregate removal was observed that compares to the current state-of-the-art processes, and recoveries of 90% were achieved,” King says.

    Within DSM Biosolutions, the custom manufacturing division that addresses fermentation processes, “customers are offered access to cutting-edge technologies in fermentation-based processes as they are continuously developed and improved for DSM’s in-house, large-scale production processes,” according to Villaume Kal, vp, DSM BioSolutions.

    “Innovations range from the latest advances in production strain construction and improvement, to fermentation process concepts, and product isolation technologies, which fit classical fermentation products as well as modern biotechnology-based products,” he says. Application examples include advanced scale-compatible expression platforms for protein production, multiple modes of fermentation process execution, and high-performance product isolation and purification operations.

    DSM Pharma Biotech offers multiple technologies, including mammalian cell culture-based antibodies and protein production, biomanufacturing, microbial fermentation, green chemistry for synthesis optimization, applying chemo/biocatalysis, and sterile filling of high-end pharmaceuticals.

    “In the third quarter of 2013, DSM will open a new production facility in Brisbane, Australia, providing these same technologies at development and commercial scale, as well as larger bioreactor sizes that are well-suited to commercial-scale fed batch processes,” King adds. “We also offer regulatory support and analytical services.”

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »